Emerging companies can expedite growth through partnering and/or VC financing. We aim to address the key steps, opportunities, bottlenecks and challenges in the partnering process versus criteria for an alternative VC financing. In the first part, Helmut Kessmann will provide an overview on the partnering / licensing option and potential scenarios. Markus Goebel will then elaborate on how a major Pharma and Investment Fund will look at these companies and assets and the key criteria to evaluate such opportunities.
18:00 – Welcome & introduction to BaseLaunch, CTI, LSZYSN
Stephan Emmerth, BaseLaunch; Stefan Blarer, CTI; Daniel Gaul, LSYZN
18:15 – Emerging company perspective
Helmut Kessmann, Polyphor, T3 Pharma
Corporate VC perspective
Markus Goebel, Novartis Venture Fund
19:15 – Networking
Participation is free of charge but registration is compulsory.